Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"NuFund Venture Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Vasa Therapeutics

    Menu

    Vasa Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vasa Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging

              Details:

              The net proceeds will be used to advance novel therapies for cardiovascular aging, including VS-041, the first potential personalized medicine-based treatment of heart failure with preserved ejection fraction (HFpEF).

              Lead Product(s): VS-041

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: VS-041

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: NuFund Venture Group

              Deal Size: $6.0 million Upfront Cash: Undisclosed

              Deal Type: Financing January 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY